GLP-1 therapies are increasingly relevant in managing non-alcoholic fatty liver disease (NAFLD), a condition marked by excessive liver fat and inflammation. By reducing inflammation and promoting liver health, GLP-1 analogs have shown promise in reversing NAFLD progression. Their ability to decrease liver fat accumulation, coupled with effects on weight loss, makes GLP-1 therapies beneficial for NAFLD and liver-related metabolic disorders. Clinical use of GLP-1 analogs may therefore offer dual benefits for managing diabetes and liver health in patients with these overlapping conditions.
Mehdi, S.F., Pusapati, S., Anwar, M.S., Lohana, D., Kumar, P., Nandula, S.A., Nawaz, F.K., Tracey, K., Yang, H., LeRoith, D., Brownstein, M.J. and Roth, J., 2023. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Frontiers in Immunology
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about Intex Sema by Intex Pharma, consult with your doctor or healthcare professional.
Mehdi, S.F., Pusapati, S., Anwar, M.S., Lohana, D., Kumar, P., Nandula, S.A., Nawaz, F.K., Tracey, K., Yang, H., LeRoith, D., Brownstein, M.J. and Roth, J., 2023. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Frontiers in Immunology
Mehdi, S.F., Pusapati, S., Anwar, M.S., Lohana, D., Kumar, P., Nandula, S.A., Nawaz, F.K., Tracey, K., Yang, H., LeRoith, D., Brownstein, M.J. and Roth, J., 2023. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Frontiers in Immunology
Mehdi, S.F., Pusapati, S., Anwar, M.S., Lohana, D., Kumar, P., Nandula, S.A., Nawaz, F.K., Tracey, K., Yang, H., LeRoith, D., Brownstein, M.J. and Roth, J., 2023. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Frontiers in Immunology
Home
